Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study

被引:0
|
作者
Ma, Hongling [1 ]
Gong, Zhaotang [1 ,2 ]
Wu, Rihan [1 ]
Siri, GuLeng [1 ]
机构
[1] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Pharm, 20 Zhaowuda Rd, Hohhot 010017, Inner Mongolia, Peoples R China
[2] Inner Mongolia Med Univ, Dept Pharm, Hohhot, Inner Mongolia, Peoples R China
关键词
anemia; clinical prediction model; linezolid; MIMIC-IV; rational use; THROMBOCYTOPENIA;
D O I
10.1177/20420986241279128
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Linezolid-induced anemia (LI-AN) is a severe adverse reaction, but risk factors of the LI-AN for elderly patients have not been established.Objectives: The objective of this study was to develop a nomogram capable of predicting LI-AN in elderly patients.Design: This is a retrospective study to develop and validate a nomogram for anemia prediction in elderly patients treated with linezolid.Methods: We retrospectively screened elderly patients treated with linezolid at Inner Mongolia People's Hospital from January 2020 to December 2023 and validated our findings using the MIMIC-IV 2.2 database. Anemia was defined as hemoglobin reduction to 75% of baseline value. Univariate and multivariable logistic regression models were used to identify predictors and construct the nomogram, which was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plot, and decision curve analysis.Results: A total of 231 patients were enrolled in this study. The training set comprised 151 individuals, and anemia occurred in 28 cases (18.54%). In the external validation set of 80 individuals, 26 (32.5%) were diagnosed with anemia. The predictors included duration of linezolid therapy, patient estimated glomerular filtration rate value, and sequential organ failure assessment score >= 2. The ROC curve for the training set was 0.830 (95% CI: 0.750-0.910), while a similar ROC curve of 0.743 (95% CI: 0.621-0.865) was obtained for the validation set. The calibration curve demonstrated good correlation between predicted and observed results, indicating that this study effectively predicts risk factors associated with LI-AN in elderly patients.Conclusion: The developed prediction model can provide valuable guidance for clinicians to prevent anemia and facilitate rational linezolid use in elderly patients. Study analyzing the clinical data of elderly patients using linezolid to better understand what factors may contribute to anemia in patientsWhy was the study done? This study aimed to develop a tool that predicts the risk of anemia in elderly patients treated with linezolid, a medication that can cause severe side effects like low hemoglobin levels. Identifying factors that contribute to this adverse reaction can help doctors prevent it and ensure safer use of linezolid.What did the researchers do? The researchers studied the medical records of elderly patients treated with linezolid at Inner Mongolia People's Hospital over a 4-year period. To better understand which factors are related to the occurrence of anemia, so we can find ways to predict the occurrence of problems.What did the researchers find? Factors that increase the risk of anemia after using linezolid include the duration of use of linezolid, kidney function, and SOFA score, that is, the longer the use of linezolid, the worse the kidney function, the higher the SOFA score, and the more likely the patient is to develop anemia.What do the findings mean? The researchers successfully created a tool, called a prediction model, which can help doctors predict the likelihood of anemia in elderly patients taking linezolid. This can guide clinicians in monitoring and managing patients more effectively, potentially reducing the occurrence of anemia and ensuring safer use of linezolid in elderly populations.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia
    Hanai, Yuki
    Matsuo, Kazuhiro
    Ogawa, Mild
    Higashi, Ayaka
    Kimura, Itsuki
    Hirayama, Shinobu
    Kosugi, Takayoshi
    Nishizawa, Kenji
    Yoshio, Takashi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (7-8) : 536 - 542
  • [2] Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients
    Hirano, Ryuichi
    Sakamoto, Yuichi
    Tachibana, Naoki
    Ohnishi, Motoki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (04) : 795 - 799
  • [3] A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil
    Lima, Leticia Souza
    Brito, Eliana da Costa Alvarenga
    Mattos, Karine
    Parisotto, Eduardo Benedetti
    Perdomo, Renata Trentin
    Weber, Simone Schneider
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (03) : 230 - 237
  • [4] Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients
    Ryuichi Hirano
    Yuichi Sakamoto
    Naoki Tachibana
    Motoki Ohnishi
    International Journal of Clinical Pharmacy, 2014, 36 : 795 - 799
  • [5] Prediction of risk factors for linezolid-induced thrombocytopenia based on neural network model
    Zhao, Xian
    Peng, Qin
    Hu, Dongmei
    Li, Weiwei
    Ji, Qing
    Dong, Qianqian
    Huang, Luguang
    Piao, Miyang
    Ding, Yi
    Wang, Jingwen
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study
    Kim, Hyung-Sook
    Lee, Eunsook
    Cho, Young-Jae
    Lee, Yeon Joo
    Rhie, Sandy Jeong
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (01) : 84 - 90
  • [7] Development and validation of a nomogram to predict linezolid-induced thrombocytopenia in hospitalized adults
    Yang, Ya
    Hu, Xiaogang
    Ran, Ya
    Wang, Hongqian
    Fu, Peishu
    Wan, Pengpeng
    Deng, Zhongqing
    Lang, Xiaoqin
    Wang, Ning
    Sun, Fengjun
    Fan, Yahan
    Jia, Yuntao
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01)
  • [8] Risk factors for linezolid - induced haematological toxicity in patients: a retrospective study
    Mo, Kai
    Cao, Wen
    Lu, Yating
    Li, Juman
    Wei, Ruhua
    Meng, Mingwei
    Liang, Yinge
    Zhong, Hui
    Qin, Yane
    Lan, Xiaobu
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2024, 18 (08): : 1258 - 1264
  • [9] Rapid Onset and Recovery Linezolid-Induced Thrombocytopenia: A Large-Sample , Single-Center Retrospective Cohort Study
    AL Qamariat, Zahra
    Aljaffar, Amnah A.
    Alabdulaal, Zahra Salman
    Alnezir, Fatima
    Al-Zawad, Weaam M.
    Alqattan, Mohammed
    Almahdi, Abdulmohsen
    DRUG HEALTHCARE AND PATIENT SAFETY, 2024, 16 : 43 - 49
  • [10] Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases
    Choi, Go Wun
    Lee, Ju-Yeun
    Chang, Min Jung
    Kim, Young Kyung
    Cho, Yoonsook
    Yu, Yun Mi
    Lee, Euni
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (02) : 228 - 234